1. Background {#sec206632}
=============

There are several factors which can cause hepatitis, including certain drugs, chemicals, and infectious agents ([@A39196R1]). Different infectious agents' resulting viruses are involved in the pathogenesis of hepatitis, such as hepatitis viruses A, B, C, D, and, E ([@A39196R2]). Among these diseases, hepatitis B and C are considered to be more serious and can become chronic ([@A39196R3], [@A39196R4]). Hepatitis C (HCV) is a viral infection that causes either acute or chronic liver inflammation ([@A39196R5]). HCV is from the *Flaviviridae* family and the hepacivirus genus, and has a single-strand RNA (ribonucleic acid) genome ([@A39196R6]). It leads to inflammation of the liver, and is one of the most common causes of liver transplants in the world ([@A39196R7]-[@A39196R9]). In 70% of cases, the disease becomes chronic; self-improvement may occur in 30% of cases ([@A39196R10]). Annually, three to five million people are infected with the virus worldwide, and it is estimated that 170 million people are currently infected with the virus around the world ([@A39196R5]). Chronic infection with HCV causes deaths due to decompensated cirrhosis, end-stage liver disease, and hepatocellular carcinoma ([@A39196R11]).

HCV has high molecular diversity, six major genotypes (named from 1- 6), and over 70 sub-genotypes named a, b, and c ([@A39196R12]). Therapeutic programs usually begin with rapid determination of HCV genotypes, because genotyping influences the duration of treatment and the impact of the sustained virological response (SVR) ([@A39196R13]). The genetic code reveals that a high ratio of amino acids are encoded by multiple (two to six) codons, which generally differ only at the third codon's nucleotide ([@A39196R14], [@A39196R15]). This understanding has led to the identification of some important facts about the virus, as patterns of codon usage vary among species ([@A39196R16]). Although each codon is specific to only one amino acid, a single amino acid may be coded by more than one codon. Such groups of codons coding a single amino acid are known as synonymous codons (e.g., there are six synonymous codons of leucine). In total, 18 of the 20 amino acids can be encoded by more than one codon due to variations at the third nucleotide position within a particular codon. Codon usage bias refers to differences in the frequency of occurrence of synonymous codons in coding DNA ([@A39196R17]). Codon usage study can help clarify the evolution of a particular species ([@A39196R14]). Recent studies have shown that synonymous codons or the equivalent of an amino acid are not used with the same frequency, and each type of codon usage, in organisms and even between the genes of one organism, is different ([@A39196R18]).

As HCV exhibits high genetic diversity, this poses a challenge for the improvement of vaccines and pan-genotypic treatment methods ([@A39196R19]). Multiple genotypes and subtypes of HCV have been identified via the analysis of nucleotide sequences ([@A39196R20]). Characterization of these genetic properties and the possible differences between these genotypes is likely to facilitate and contribute to the development of effective prevention and treatment protocols against HCV infection ([@A39196R21]). Previously, we were the first to have studied rare codon clusters (RCCs) and their locations in structures of HCV proteins ([@A39196R22]).

2. Objectives {#sec206633}
=============

In this project, a bioinformatic study of different genotypes of HCV was conducted to check the phylogenetical differences between these genotypes, as well as the amino acid codon usage in the structure of the virus. It was hoped that more precise and effective approaches could then be chosen for treatment regimens using the findings of this study.

3. Methods {#sec206637}
==========

3.1. HCV Genome Sequences {#sec206634}
-------------------------

For the bioinformatic analysis, the nucleotide sequences and features of the six genotypes of HCV were obtained from the following website : http://www.ncbi.nlm.nih.gov/genome/genomes/10312 ([Table 1](#tbl52170){ref-type="table"}).

###### Genetic Properties of HCV Genotypes

                   HCV-G1                                              HCV-G2                                           HCV-G3                                           HCV-G4                                           HCV-G5                                           HCV-G6
  ---------------- --------------------------------------------------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------
  **Locus**        NC_004102, 9646 bp ss-RNA linear, VRL 17-JUN-2016   NC_009823, 9711 bp RNA linear, VRL 26-JUL-2011   NC_009824, 9456 bp RNA linear, VRL 27-JUL-2011   NC_009825, 9355 bp RNA linear, VRL 26-JUL-2011   NC_009826, 9343 bp RNA linear, VRL 26-JUL-2011   NC_009827, 9628 bp RNA linear, VRL 26-JUL-2011
  **Accession**    NC_004102                                           NC_009823                                        NC_009824                                        NC_009825                                        NC_009826                                        NC_009827
  **Version**      NC_004102.1, GI:22129792                            NC_009823.1, GI:157781212                        NC_009824.1, GI:157781216                        NC_009825.1, GI:157781208                        NC_009826.1, GI:157781210                        NC_009827.1, GI:157781214
  **Serotype**     1a                                                  2a                                               3a                                               4a                                               5a                                               6b
  **Db_Xref**      Taxon:11103, GeneID:951475                          Taxon:40271, GeneID:11027172                     Taxon:356114, GeneID:11027185                    Taxon:33745, GeneID:11027168                     Taxon:33746, GeneID:11027170                     Taxon:42182, GeneID:11027174
  **Protein ID**   NP_671491.1                                         YP_001469630.1                                   YP_001469631.1                                   YP_001469632.1                                   YP_001469633.1                                   YP_001469634.1
  **Db_Xref**      GI:22129793, GeneID:951475                          GI:157781213 GeneID:11027172                     GI:157781217, GeneID:11027185                    GI:157781209, GeneID:11027168                    GI:157781211, GeneID:11027170                    GI:157781215, GeneID:11027174

3.2. Analysis of Codon Usage {#sec206635}
----------------------------

In the next step, the frequency, number, and fraction of 61 codons for each amino acid were evaluated within the structure of HCV proteins, and the preferred codons were extracted using the information provided on the *Gene Infinity* website: http://www.geneinfinity.org/sms/sms_codonusage.html ([@A39196R23]) ([Table 2](#tbl52171){ref-type="table"}).

###### The Nucleotide Compositional Properties of the Six HCV Genotypes

                   HCV-G1   HCV-G2   HCV-G3   HCV-G4   HCV-G5   HCV-G6
  ---------------- -------- -------- -------- -------- -------- --------
  **%G1 + C1**     57.39    55.75    56.60    56.07    56.47    55.81
  **%G1 + A1**     57.62    57.96    56.47    58.06    57.60    57.80
  **%G1 + T1**     51.94    53.02    52.86    52.78    51.96    52.10
  **%A1 + T1**     42.61    44.25    43.40    43.93    43.53    44.19
  **%A1 + C1**     48.06    46.98    47.14    47.22    48.04    47.90
  **%C1 + T1**     42.38    42.04    43.53    41.94    42.40    42.20
  **%G2 + C2**     50.61    50.35    50.45    49.29    49.70    50.15
  **%G2 + A2**     44.54    43.52    44.65    43.80    44.72    44.05
  **%G2 + T2**     49.62    48.60    48.59    48.35    48.64    48.79
  **%A2 + T2**     49.39    49.65    49.55    50.71    50.30    49.85
  **%A2 + C2**     50.38    51.40    51.41    51.65    51.36    51.21
  **%C2 + T2**     55.46    56.48    55.35    56.20    55.28    55.95
  **%G3 + C3**     68.58    66.24    59.91    63.05    64.76    61.08
  **%G3 + A3**     43.08    44.21    44.36    44.60    44.16    45.28
  **%G3 + T3**     47.86    47.25    49.55    47.09    48.74    48.56
  **%A3 + T3**     31.42    33.76    40.09    36.95    35.24    38.92
  **%A3 + C3**     52.14    52.75    50.45    52.91    51.26    51.44
  **%C3 + T3**     56.92    55.79    55.64    55.40    55.84    54.72
  **%G3s + C3s**   67.20    64.60    58.08    61.48    63.29    59.34

Also, phylogenetic analysis and the evolutionary relationship of HCV genotypes were evaluated using *MEGA 7* software ([@A39196R24]). The analysis of the deduced amino acid sequences from the collected samples and data obtained from GenBank was performed through the construction of a phylogenetic tree with maximum parsimony using *MEGA 7*. The frequencies of the used codons were reported as descriptive statistics. The software Minitab version 16.0 was used for statistical analysis ([@A39196R24]).

3.3. Compositional Properties Measures {#sec206636}
--------------------------------------

To examine the compositional properties of the six HCV sequences, GC~1s,2s,3s~, GA~1s,2s,3s~, GT~1s,2s,3s~, AT~1s,2s,3s~, AC~1s,2s,3s~, and CT~1s,2s,3s~(the frequencies of nucleotide G + C, G+A, G+T, A+T, A+C, and C+T at the first, second and third codon position) within each open reading frame (ORF) were calculated. This calculation was done using the *CAIcal* web server ([@A39196R25]).

4. Results {#sec206641}
==========

4.1. Cluster Codon Analysis {#sec206638}
---------------------------

The results of the cluster codon analysis showed that the codon usage for terminal nucleotides of all amino acids included C and G. For example, the amino acids alanine (Ala), glycine (Gly), tyrosine (Tyr), and valine (Val), which each have four codon codes, had reported terminal nucleotides with codon usage of C or G. The results of the cluster codon analysis also showed that genotypes were divided into two groups with 4% similarity: genotypes 1, 5, and 3 in one group, and genotypes 2, 6, and 4 in the other group. In the first group, genotypes 1 and 5 had the highest similarity of codon usage (74.02%), and in the second group, genotypes 2 and 6 showed the highest similarity of codon usage (72.43%). The most differences in codon usage were detected between genotype 1 from the first group and genotype 4 from the second group, with 4% similarity in terms of preferred codons ([Figure 1](#fig38055){ref-type="fig"}).

![Similarity of Codon Usage Between HCV Genotypes](hepatmon-16-10-39196-i001){#fig38055}

Phylogenetic analysis of the genotypes showed that closest resemblances were between genotypes 1 and 4 ([Figure 2](#fig38056){ref-type="fig"}). The close proximity of the genotypes 1 and 4 in the tree diagram represented a similarity in their gene and protein sequence, but codon usage analysis showed that genotypes 1 and 4 had minimal similarity and maximal distance. This phylogenetic analysis also indicated that genotypes 1 and 2 had the most significant phylogenetical distance ([Figure 2](#fig38056){ref-type="fig"}).

![Molecular Evolution and Phylogenetic Diagram of HCV Genotypes](hepatmon-16-10-39196-i002){#fig38056}

4.2. Compositional Properties of the Genomes in HCV Genotypes {#sec206639}
-------------------------------------------------------------

The compositional properties of the genomes of the six HCV genotypes in the *CAIcal* web server showed that these HCV genotypes have the similar contents of GC~1s,2s,3s~, GA~1s,2s,3s~, GT~1s,2s,3s~, AT~1s,2s,3s~, AC~1s,2s,3s~, and CT~1s,2s,3s~([Table 3](#tbl52172){ref-type="table"}). It was found that the frequency of GC~1s,\ 2s,\ 3s~ was higher in comparison with other nucleotide compositions. The minimum frequency of nucleotide composition belonged to AT~3s~. These results showed that HCV is a GC abundant virus.

###### The Frequency, Number, and Fraction of Each of the 61 Codons for Each Amino Acid in the Protein Structure of HCV Genotypes

  Amino Acids          Codon   HCV-G1   HCV-G2   HCV-G3   HCV-G4   HCV-G5   HCV-G6                                      
  -------------------- ------- -------- -------- -------- -------- -------- -------- ------ ------ ------ ------ ------ ------
  **Ala**              GCG     64       0.23     61       0.22     52       0.19     55     0.21   56     0.21   50     0.19
  GCA                  46      0.17     42       0.15     54       0.20     49       0.19   50     0.18   55     0.21   
  GCT                  55      0.20     76       0.28     81       0.30     69       0.26   58     0.21   70     0.27   
  GCC                  112     0.40     97       0.35     87       0.32     90       0.34   109    0.40   89     0.34   
  **Cys**              TGT     32       0.31     21       0.24     30       0.31     25     0.29   37     0.37   41     0.41
  TGC                  71      0.69     66       0.76     66       0.69     61       0.71   62     0.63   58     0.59   
  **Asp**              GAT     33       0.28     38       0.29     55       0.42     40     0.30   36     0.28   44     0.34
  GAC                  86      0.72     91       0.71     77       0.58     95       0.70   93     0.72   87     0.66   
  **Glu**              GAG     84       0.72     87       0.77     76       0.66     79     0.70   62     0.58   84     0.76
  GAA                  32      0.28     26       0.23     40       0.34     34       0.30   45     0.42   27     0.24   
  **Phe**              TTT     31       0.36     39       0.43     36       0.38     28     0.30   27     0.29   41     0.48
  TTC                  56      0.64     52       0.57     59       0.62     66       0.70   65     0.71   45     0.52   
  **Gly**              GGG     74       0.29     87       0.33     24       0.30     61     0.25   92     0.36   65     0.26
  GGA                  35      0.14     44       0.17     47       0.19     48       0.20   34     0.13   50     0.20   
  GGT                  42      0.16     26       0.10     52       0.21     44       0.18   51     0.20   51     0.21   
  GGC                  104     0.41     105      0.40     73       0.30     91       0.37   80     0.31   80     0.33   
  **His**              CAT     20       0.43     20       0.34     43       0.61     28     0.38   28     0.40   27     0.38
  CAC                  38      0.57     39       0.66     27       0.39     46       0.62   42     0.60   45     0.62   
  **Ile**              ATA     33       0.25     30       0.22     40       0.32     31     0.23   33     0.25   40     0.29
  ATT                  24      0.18     31       0.23     25       0.20     27       0.20   32     0.24   27     0.20   
  ATC                  74      0.56     75       0.55     61       0.48     76       0.57   69     0.51   71     0.51   
  **Lys**              AAG     63       0.68     60       0.59     61       0.66     69     0.68   84     0.72   48     0.58
  AAA                  30      0.32     42       0.41     32       0.34     33       0.32   33     0.28   42     0.42   
  **Leu**              TTG     38       0.12     55       0.18     54       0.18     51     0.17   46     0.15   54     0.18
  TTA                  9       0.03     23       0.08     21       0.07     22       0.07   24     0.08   15     0.05   
  CTG                  98      0.32     63       0.21     70       0.24     70       0.24   75     0.24   68     0.23   
  CTA                  21      0.07     33       0.11     34       0.11     28       0.09   32     0.10   37     0.12   
  CTT                  52      0.17     40       0.13     48       0.16     51       0.17   56     0.18   36     0.12   
  CTC                  87      0.29     88       0.28     69       0.23     75       0.25   74     0.24   88     0.30   
  **Met**              ATG     56       1.00     72       1.00     63       1.00     55     1.00   55     1.00   62     1.00
  **Asn**              AAT     25       0.29     30       0.39     26       0.33     46     0.51   36     0.40   31     0.51
  AAC                  61      0.71     46       0.61     53       0.67     44       0.49   53     0.60   47     0.49   
  **Pro**              CCG     34       0.16     33       0.16     30       0.14     42     0.21   48     0.22   33     0.16
  CCA                  35      0.17     41       0.19     57       0.27     57       0.28   31     0.14   46     0.22   
  CCT                  56      0.27     46       0.22     60       0.29     45       0.22   47     0.22   62     0.30   
  CCC                  82      0.40     91       0.43     63       0.30     60       0.29   91     0.42   69     0.33   
  **Gln**              CAG     52       0.59     57       0.61     55       0.59     45     0.56   53     0.62   58     0.46
  CAA                  36      0.41     36       0.39     39       0.41     35       0.44   33     0.38   32     0.36   
  **Arg**              AGG     53       0.30     47       0.27     33       0.18     34     0.20   43     0.25   43     0.25
  AGA                  26      0.14     30       0.17     30       0.16     37       0.22   29     0.17   36     0.21   
  CGG                  34      0.19     33       0.19     31       0.17     28       0.17   36     0.21   27     0.16   
  CGA                  13      0.07     14       0.08     17       0.09     14       0.08   12     0.07   13     0.08   
  CGT                  15      0.08     16       0.09     26       0.14     13       0.08   17     0.10   20     0.12   
  CGC                  38      0.21     32       0.19     45       0.25     43       0.25   32     0.19   32     0.19   
  **Ser**              AGT     15       0.07     19       0.09     22       0.10     13     0.06   17     0.08   21     0.09
  AGC                  49      0.23     36       0.16     45       0.20     43       0.20   41     0.20   45     0.20   
  TCG                  25      0.12     27       0.12     24       0.11     34       0.16   21     0.10   26     0.11   
  TCA                  27      0.13     30       0.13     33       0.14     41       0.19   28     0.14   49     0.22   
  TCT                  28      0.13     36       0.16     44       0.19     37       0.17   36     0.18   40     0.18   
  TCC                  70      0.33     75       0.34     60       0.26     48       0.22   58     0.29   46     0.20   
  **Thr**              ACG     50       0.23     35       0.15     34       0.16     34     0.15   49     0.23   43     0.19
  ACA                  33      0.15     52       0.23     51       0.23     52       0.22   44     0.20   58     0.25   
  ACT                  44      0.20     52       0.23     62       0.28     50       0.22   44     0.20   45     0.20   
  ACC                  89      0.41     89       0.39     72       0.33     96       0.41   79     0.37   84     0.37   
  **Val**              GTG     98       0.41     90       0.39     87       0.38     98     0.39   83     0.36   91     0.38
  GTA                  25      0.10     23       0.10     32       0.14     37       0.15   34     0.15   38     0.16   
  GTT                  35      0.15     30       0.13     35       0.15     39       0.16   43     0.19   40     0.17   
  GTC                  83      0.34     89       0.38     74       0.32     77       0.31   69     0.30   71     0.30   
  **Trp**              TGG     71       1.00     68       1.00     69       1.00     68     1.00   66     1.00   67     1.00
  **Tyr**              TAT     29       0.30     38       0.37     39       0.37     38     0.38   35     0.35   41     0.41
  TAC                  69      0.70     66       0.63     66       0.63     62       0.62   66     0.65   58     0.59   
  **Terminal Codon**   TGA     1.00     1.00     1.00     1.00     1.00     1.00     0.00   0.00   1.00   1.00   0.00   0.00
  TAG                  0.00    0.00     0.00     0.00     0.00     0.00     1.00     1.00   0.00   0.00   1.00   1.00   
  TAA                  0.00    0.00     0.00     0.00     0.00     0.00     0.00     0.00   0.00   0.00   0.00   0.00   

4.3. Prevalence of Preferred (Used) Codons {#sec206640}
------------------------------------------

[Figure 3](#fig38057){ref-type="fig"} shows the prevalence of the preferred (used) codons in the HCV genotypes. Here, it can be seen which codon is preferred and used more than other codons. The results showed that the most preferred codon usage for all of the amino acids was, in order, as follows: Ala (GCC), Cys (TGC), Asp (GAC), Glu (GAG), Phe (TTC), Gly (GGC), His (CAC), Ile (ATC), Lys (AAG), Leu (CTC), Asn (AAC), Pro (CCC), Gln (CAG), Arg (AGG), Ser (TCC), Thr (ACC), Val (GTG), Tyr (TAC), and the stop codon (TGA-TAG). Also, the least preferred codons for all of the amino acids was, in order, as follows: Ala (GCA), Cys (TGT), Asp (GAT), Glu (GAA), Phe (TTT), Gly (GGA), His (CAT), Ile (ATT), Lys (AAA), Leu (TTA), Asn (AAT), Pro (CCG), Gln (CAA), Arg (CGA), Ser (AGT), Thr (ACG), Val (GTA), Tyr (TAT), and the stop codon (TAA; not used). Met (ATG) and Trp (TGG) had one codon. The results of the cluster codon analysis also showed that the lowest codon usages for terminal nucleotides among all amino acids, with the exception of Met, Trp, Thr, and Pro, were A and T.

![Frequency of Used Codons in HCV Genotypes](hepatmon-16-10-39196-i003){#fig38057}

5. Discussion {#sec206642}
=============

HCV is the leading causes for chronic liver disease ([@A39196R1], [@A39196R2]), with the possibility of leading to chronic hepatitis and eventually hepatocellular carcinoma (HCC) ([@A39196R26]). In addition to the clinical and epidemiological significance of HCV, genotyping has significant prognostic value and can be used to help determine the progress and treatment protocols of the disease ([@A39196R21]). The amino acid sequences of proteins are determined by three nucleotide codons. Living organisms use standard genetic codes including 61 codons for 20 amino acids, with some amino acids having more than one codon. The pressure on the translated codons is to prefer (use) some codons rather than others for effective protein expression ([@A39196R27]). Changes in the patterns of codon usage can lead to changes in response to the treatment of nucleotide-like drugs. Genotypes that have the greatest differences in codon usage may lead to significant differences in the response to and duration of treatments with the same drug regimens. The reason can be attributed to the pattern of using similar nucleotide codons in these two genotypes.

In this study, the biggest similarities in codon usage were observed between genotypes 1 and 5; therefore, it was expected that the results regarding the dosage and treatment protocol for genotypes 1 and 4 would be reversed. Despite the significant differences in codon usage among genotypes 1 and 4, the two genotypes had the phylogenetically closest resemblances, indicating more similarities in their genome and protein sequences. The most significant phylogenetical difference was observed between genotypes 1 and 2, which indicated that these two genotypes had the greatest difference in terms of the sequences of genomes and protein.

The results of the codon usage analysis showed that some codon usages, such as Gln (CAG, CAA), Ser (AGC), and Trp (TGG), had very similar frequencies in all of the HCV genotypes. This result is very important, as these residues may have a critical role in determining the final structure of the HCV proteins. However, it is essential to confirm this conclusion with more experimental evidence.

As the results of this study showed, the most preferred terminal nucleotides in codon usage for all of the amino acids were C and G. Consequently, the least preferred terminal nucleotides in codon usage for all of the amino acids were T and A. This is a very important finding, and as previously reported, an additional layer of hidden information lies within the codon sequence and beyond the amino acid sequence ([@A39196R28]). Studies of such hidden information in codon sequences can reveal the molecular evolution of the organisms, and provide insights into the functional categories and histories of the genes in the respective genome. Codon usage analysis can also contribute to understanding the interaction between RNA viruses and the immune responses of the hosts ([@A39196R29]). These findings showed that all of the transfer RNAs (tRNA) had C and G in the first nucleotides for anti-codon usage among all of the amino acids and, consequently, codon-anti-codon interaction in messenger RNA (mRNA) translation would be very strong. As a result, the average binding energy in codon-anti-codon interaction in hepatitis C is more than that with human cell interaction with HCV, and the mRNA and tRNA translation is stronger here than among similar human cell components ([@A39196R30]). Based on the nucleotide structure of the codons, different used codons have special interactive affinity to anti-codons, and this thus leads to different powers of translation. Used codons that have C and G nucleotides in their structures have more energy in their affinity to anti-codons. The exact calculation of this energy can help us to better understand the mechanisms of successful HCV replication and pathogenicity.

In this study, we were able to detect a layer of hidden information within the codon sequences of HCV genomes. Here, we report these findings for the first time, and we believe that they are very critical for planning new research projects and designing new drugs that will influence codon-anti-codon interaction. The findings of such bioinformatic studies can be used for further practical research and clinical trials, and help us establish a better understanding of HCV replication and pathogenesis. Such an analysis conducted on other viral agents of hepatitis could also provide new insights in the field of viral behavior.
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